Inovio Pharmaceuticals Inc
INO
Get informed when a big investor buys or sells
+ FollowMarket Cap$63.24M
Close$
$0.07
93.6% downside
Current Fair Value
93.6% downsideOvervalued by 93.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $63.24 Million |
|---|---|
| Enterprise Value | $-17,507,572,960.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.81 |
| Beta | 1.49 |
| Outstanding Shares | 691,019,000 |
Return
| Return on Equity | -1399.93% |
|---|---|
| Return on Assets | -170.65% |
| Return on Invested Capital | -732.44% |
Valuation & Multiples
| P/E Ratio | -0.69 |
|---|---|
| PEG | 0.69 |
| Price to Sales | -1.16 |
| Price to Book Ratio | 0.15 |
| Enterprise Value to Revenue | 267933.41 |
| Enterprise Value to EBIT | 0.2 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.5 |
| Debt to Equity | 1.43 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 18, 2026
EPS Estimate
$-0.37
Average shareholder expectationRevenue Estimate
$333,333
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
$533,333
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 55.42% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 6.69% |
|---|---|
| Total Invested | $14,250▼ 99.97% |
| Investors Holding | 5▼ 102.00% |
ESG Score
No data
About Inovio Pharmaceuticals Inc
CEO: Jong Kim